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Abstract
Eradication of Helicobacter pylori usually consists of a 7-day course of triple therapy including
metronidazole or amoxicillin plus clarithromycin plus a proton pump inhibitor. We report about a
rare adverse event of Hp eradication in a patient with moderate chronic and moderate active
pangastritis. Shortly after the end of treatment cholestatic hepatitis occurred which was most likely
related to clarithromycin, perhaps enhanced by amoxicillin. Since liver dysfunction was self-limited,
no further treatment was required. In summary, clinicians should be aware about the presented
rare adverse event of Helicobacter pylori eradication treatment for a close monitoring of those
patients and rapid management of acute liver failure.
Introduction
According to the current DGVS (German Association of
Gastroenterologists) S3-guidelines eradication of Helico-
bacter pylori (Hp) is indicated in patients with gastric or
duodenal ulcer and gastric marginal zone B-cell lym-
phoma of MALT-type (mucosa-associated lymphoid tis-
sue). It is facultative in patients with dyspepsia (following
upper GI endoscopy), chronic asymptomatic Hp-associ-
ated gastritis, Mënëtrier's disease, idiopathic thrombocy-
topenic purpura, and lymphocytic gastritis [1]. A 7-day
course of triple therapy is recommended including metro-
nidazole or amoxicillin plus clarithromycin plus a proton
pump inhibitor (PPI). Common adverse events of clari-
thromycin are nausea, vomiting, abdominal tenderness,
diarrhea, (very) rare adverse events are crampy abdominal
pain, pseudomembranous colitis, acute pancreatitis,
elvated liver enzymes, interstitial nephritis, hypersensitiv-
ity reaction, "Torsades de pointes" tachycardia, tinnitus,
hearing loss, dizziness, confusion, anxiety, sleeplessness,
nightmares, hallucinations, psychosis, headache,
hypoglycemia, leukopenia, and thrombocytoenia
(according to patient information leaflet). Amoxicillin my
induce diarrhea, gastritis, stomatitis, nausea, vomiting,
glossitis, darkening of the tongue, enterocolitis, pseu-
domembranous colitis, hypersensitivity reaction, mild
elevation of ASAT, anemia, thrombocytopenia, eosi-
nophilia, and agranulocytosis (according to patient infor-
mation leaflet).
Case presentation
In August 2008, a 64-year-old Caucasian male German
presented at our outpatient department with complaints
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of nausea, knife-like pain in the right upper quadrant of
the abdomen, which occurred after the intake of food, and
additional globus pharyngis feeling. He had a past medi-
cal history of arterial hypertension, hyperuricemia, benign
paroxysmal positional vertigo, and was allergic to
diclofenac. The list of drugs he was taken included 6 mg
betahistine q.d., 150 mg allopurinol q.d., 25 mg
carvedilol q.d., 80 mg valsartan b.i.d., and 25 mg hydro-
chlorothiazide q.d. Initial laboratory investigation
showed increased levels for ASAT [67 U/L (normal ≤35)],
ALAT [67 U/L (normal ≤45)], GGT [87 U/L (normal
≤55)], and bilirubin [22 μmol/L (normal < 20)] (Figure
1).
Abdominal ultrasound demonstrated fatty liver disease,
pancreas, biliary tract, and portal vein were non-accessi-
ble. Upper GI endoscopy with biopsies and rapid urease
test displayed moderate chronic and moderate active Hp
pangastritis. In contrast, colonoscopy was unremarkable.
Hp eradication therapy was prescribed, including 1 g
amoxicillin b.i.d., 500 mg clarithromycin b.i.d. and 40 mg
pantoprazole b.i.d. (ZacPac™) for a duration of seven
days. One day after end of treatment the patient presented
with a burning sensation in his throat, side stitch, mouth
dryness, dark urine, and anal pruritus. Laboratory investi-
gation showed further increased levels for ALAT [86 U/L]
and GGT [185 U/L], and stably elevated levels for ASAT
[59 U/L] and bilirubin [24 μmol/L] (Figure 1). Two weeks
later, the patient was admitted to the Department of Sur-
gery because of abdominal tenderness, especially after
deep liver palpation, and loss of appetite including weight
loss of 3 kg (BMI 26 kg/m2). Laboratory investigation
showed further increased levels for ASAT [73 U/L], ALAT
[1351 U/L] and GGT [344 U/L], with bilirubin level
remaining unchanged [21 μmol/L] (Figure 1). Since ini-
tial surgical abdominal ultrasound was suspicious of
acute cholecystitis, the patient was treated with 3 g sultam-
icillin t.i.d. for three days. The treatment was stopped
because magnetic resonance cholangiopancreatography
(MRCP) could not confirm this diagnosis. The gallbladder
was normal without stones, as well as intra- and extrahe-
patic bile ducts and pancreatic duct. There was a small cyst
(with a diameter of 1.3 cm) in the head of the pancreas,
but no pancreatitis, pancreatic tumor, or pancreas
divisum. The patient was then transferred to the Depart-
ment of Internal Medicine. History of increased alcohol
consumption, viral hepatitis markers (HAV-IgM/G, Anti-
Hbc, Anti-HCV), α1-antitrypsin, coeruloplasmine, ferri-
tin, protein electrophoresis, and autoimmune markers
(ANA, Anti-LKM, AMA, Anti-SLA, IgG) were all negative/
normal. Liver biopsy showed mild chronic hepatitis (Fig-
ure 2) with mild portal fibrosis (Figure 3) and a 30%
micro- and macrovesicular steatosis (Figure 4), consistent
with drug- or toxin-induced liver injury. Histology sam-
ples were sent to Professor Lobeck (Pathology, Potsdam)
for a second opinion. Besides micro- and macrovesicular
steatosis (Figure 4), samples showed moderately active
intrahepatic cholangitis (Figure 2) and cholangiolitis (Fig-
ure 5), likely recurrent because of already existing portal
fibrosis (Figure 3) (DD cholestasis, chronic inflammatory
bowel disease (CED), cholangiolitic type of drug-toxic-
ity). There were no hints for viral or auto-immune hepati-
tis, nor auto-immune cholangitis. The patient was
discharged from the hospital one week later because liver
enzymes began to normalize. Two weeks later, laboratory
investigation in our outpatient department showed
decreased levels for ASAT [40 U/L], ALAT [54 U/L], and
GGT [119 U/L] (Figure 1). Level of bilirubin remained
unchanged [25 μmol/L]. Another month later, laboratory
investigation at the office of the patient's primary care
Follow-up of serum ALAT and GGT levels in a 64 year old  man with drug-induced liver injury Figure 1
Follow-up of serum ALAT and GGT levels in a 64 
year old man with drug-induced liver injury.
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Liver biopsy shows portal inflammation on hematoxylin-eosin  stain (magnification ×100) Figure 2
Liver biopsy shows portal inflammation on hematox-
ylin-eosin stain (magnification ×100).Cases Journal 2009, 2:205 http://www.casesjournal.com/content/2/1/205
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physician demonstrated further reduction of liver
enzymes with the exception of bilirubin.
Discussion
We report the case of a 64-year-old patient who presented
with unclear elevation of liver enzymes. Alcohol-induced
liver injury, viral hepatitis, auto-immune hepatitis, Wil-
son's disease, hemochromatosis, and α1-antitrypsin defi-
ciency were unlikely according to the laboratory and
histology results. Cholecysto-/choledocholithiasis could
also be excluded due to normal MRCP results and normal
alkaline phosphatase value. Liver biopsy was suspicious
for drug- or toxin-induced liver injury. Regarding the
patient's drug history it was remarkable that liver enzymes
started to raise shortly after completion of Hp eradication.
Since pantoprazole was not very likely the culprid, clari-
thromycin and amoxicillin were the drugs in suspicion. It
has been known for many years that several antibiotics
can cause severe hepatic injury [2]. In the case of the pen-
icillins, the combination amoxicillin-clavulanate and the
penicillinase-resistant penicillins oxacillin, (di-)cloxacil-
lin, and flucloxacillin can cause (mainly cholestatic) hep-
atitis. Cephalosporins have little hepatotoxicity;
ceftriaxone can cause drug-induced gallstones. The poten-
tial of erythromycin and several other macrolides to cause
(usually cholestatic) hepatitis is well established. Tetracy-
clines can cause a syndrome mimicking acute fatty liver of
pregnancy, but this complication has virtually disap-
peared. Quinolones seem to be able to cause cholestasis.
Sulfamethoxazole/trimethoprim can cause severe hepato-
toxicity, especially in patients with acquired immunodefi-
ciency syndrome (AIDS). Finally, nitrofurantoin can cause
acute cholestatic and hepatocellular reactions as well as
chronic hepatitis mimicking chronic auto-immune hepa-
titis [2]. There are three reports indicating that intrahe-
patic cholestasis [3], acute liver injury and even liver
failure [4,5] may be caused by amoxicillin alone. Possible
drug interactions include induction of anti-coagulation
effects of coumarins, inhibition of effects of contracep-
tives, and increase of hypersensitivity reactions in combi-
nation with allopurinol (according to patient information
leaflet). Regarding clarithromycin, cholestatic liver disease
[6-8] and fulminant liver failure [9] have been described
even more often in the literature [10,11]. Patients with
cholestatic liver disease present usually with minimal ele-
vations of ALAT and ASAT but significant elevations of
alkaline phosphatase and/or GGT. It appears that these
subjects have dose-related toxicity, not a hypersensitivity
Liver biopsy shows beginning portal fibrosis on Masson- Goldner stain (magnification 50×) Figure 3
Liver biopsy shows beginning portal fibrosis on Mas-
son-Goldner stain (magnification 50×).
Liver biopsy shows micro- and macrovesicular steatosis on  hematoxylin-eosin stain (magnification 100×) Figure 4
Liver biopsy shows micro- and macrovesicular stea-
tosis on hematoxylin-eosin stain (magnification 
100×).
Liver biopsy shows cholangiolitis and single cell necrosis on  hematoxylin-eosin stain (magnification 200×) Figure 5
Liver biopsy shows cholangiolitis and single cell 
necrosis on hematoxylin-eosin stain (magnification 
200×).Cases Journal 2009, 2:205 http://www.casesjournal.com/content/2/1/205
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reaction [8]. This phenomenon has already been
described in several preclinical animal models prior to the
marketing authorisation of the drug [12]. Since clarithro-
mycin is primarily metabolized in the liver the patient
information leaflet warns about administration of this
drug in patients with advanced liver dysfunction. In
patients with mild liver dysfunction, frequent monitoring
of ASAT, ALAT, GGT, alkaline phosphatase, and bilirubin
is recommended. Since clarithromycin inhibits liver
enzyme CYP3A, clinicians have to be aware that plasma
levels of drugs that are metabolized by this enzyme may
increase. Typical drugs are antiarrythmics, car-
bamazepine, colchicine, digoxine, HMG-CoA reductase
inhibitors, oral anticoagulants, sildenafile, tadalafile, var-
denafile, theophylline, tolterodine, triazolo-benzodi-
azepines, and zidovudine. In addition, there are drugs like
pimozide, astemizole, terfenadine, and ergotamine/dihy-
droergotamine that are contraindicated in combination
with clarithromycin due to increased toxicity based on
other mechanisms. Moreover, drugs like fluconazole and
ritonavire can increase plasma level of clarithromycin,
thus potentiating its side effects. However, in our case, we
could not detect any typical drug interactions. We pre-
sume that clarithromycin was the main culprid for the
increase in liver enzymes due to the empirical probability,
although an additional adverse event of amoxicillin can
not be excluded. The short course of sultamicillin admin-
istration seems to be irrelevant since liver enzyme
increased prior to onset of treatment. Interestingly, the
pattern of elevated liver enzymes was very unusual in this
case, thus significant elevation of ALAT instead of GGT/
alkaline phosphatase was the major finding. There is no
good explanation for this finding. However, we speculate
that preexisting fatty liver disease, respectively nonalco-
holic steatohepatitis (NASH) may be a prediposition for
antibiotic-induced liver injury. Steatohepatitis is charac-
terized microscopically by hepatic fat accumulation (stea-
tosis), mixed lobular inflammation, ballooning
degeneration of hepatocytes (sometimes with identifiable
Mallory bodies), glycogenated hepatocyte nuclei, and
pericellular fibrosis. These are features that could also be
found in the liver histology of our patient, although the
"chicken wire" pattern of the pericellular fibrosis, which
affects portal areas only secondarily in later stages, was not
present.
Conclusion
In summary, clinicians should be aware about the pre-
sented rare adverse event of Hp eradication treatment. In
patients with pre-existing liver disease like steatohepatitis,
a close look at concomitantly prescribed drugs and moni-
toring of ASAT, ALAT, GGT, alkaline phosphatase, and
bilirubin prior and after Hp eradication is recommended.
Although only moderate liver injury was detected in our
case, physicians should be prepared for rapid manage-
ment of acute liver failure. In addition, alternative drug
combinations, such as amoxicillin + metronidazole + PPI,
metronidazole + doxycycline + bismuth subcitrate + PPI,
or rifabutine + levofloxacine + PPI, should be discussed
for Hp eradication in these patients.
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